# LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML

> **NCT05548088** · PHASE1 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 11 (actual)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia

## Interventions

- **BIOLOGICAL:** LILRB4 STAR-T cells

## Key facts

- **NCT ID:** NCT05548088
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-25
- **Primary completion:** 2024-08-03
- **Final completion:** 2024-08-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05548088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05548088, "LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05548088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*